Stryker price target raised to $211 from $191 at BTIG

BTIG analyst Ryan Zimmerman raised his price target on Stryker to $211 and kept his Buy rating after its presentation at the recent AAOS conference, saying he is “encouraged” by the company’s core business area execution and believes that the adoption of its Mako surgery technology should “continue at a strong pace in FY19”. In spite of the increasing competition, the analyst says the management expressed that it has “no plans to change the strategy even in the midst of increasing competition” but rather “noted a slight procedural volume uptick in joint reconstruction”.
https://thefly.com/landingPageNews.php?id=2880383